NCT04802759 2026-04-13A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerHoffmann-La RochePhase 1/2 Recruiting316 enrolled
NCT04784715 2026-02-20Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)AstraZenecaPhase 3 Active not recruiting1,157 enrolled 3 FDA
NCT05150691 2026-01-28A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsDualityBio Inc.Phase 1/2 Recruiting796 enrolled